Hong Kong
May 20, 2026
Today, Great Bay Bio (GBB) announced the signing of a strategic cooperation agreement with a globally leading biosimilar enterprise to build a long‑term, forward‑looking in‑depth partnership. This collaboration integrates GBB’s AI‑powered site‑specific integration cell line development platform AlfaCell with the partner’s comprehensive industrial chain covering early‑stage R&D, clinical development, regulatory registration, manufacturing and global direct sales. Both parties will jointly provide end‑to‑end integrated services ranging from cell line construction to pre‑clinical development and commercialization. Marking another key milestone in GBB’s global expansion strategy, this partnership will accelerate the commercial rollout of AlfaCell technologies across global biosimilar and novel biotherapeutic segments. Together with industry partners, it will deliver one‑stop full‑stream solutions from target discovery to pre‑clinical development for the global biopharmaceutical sector.
As the world’s first commercialized site‑specific integration cell line development platform, AlfaCell features unique strengths of dual speediness and high productivity: it achieves RCB generation in just 1.5 months, compared with the 6‑month cycle of conventional methods, and enables early prediction of product quality within one month to streamline process development decisions and advance CMC progress. The platform delivers an average titer of over 6.9 g/L across customer projects and achieves breakthroughs in complex molecule development, especially for cutting‑edge biotherapeutics including bispecific antibodies, multispecific antibodies and ADCs. It supports titers up to 15 g/L for mAbs, 12 g/L for BsAbs (with correct pairing rates generally above 80%), and 13 g/L for nanobodies.
The partnered enterprise ranks among the world’s top‑5 biosimilar developers and top pharmaceutical companies in the Asia‑Pacific region. As a world‑class integrated biopharma leader covering R&D, manufacturing and commercialization, its core products target major disease areas including autoimmune disorders, oncology and ophthalmology, with approvals in nearly 100 countries and regions worldwide. Backed by ultra‑large production capacity, a full‑value‑chain layout and proven global regulatory expertise, the company is firmly positioned in the global top tier of biosimilar developers with leading market share. Its business spans early‑stage research, clinical trials, global registration, large‑scale manufacturing and international direct sales, enabling robust global commercialization capabilities.
This powerful alliance realizes complementary strengths and mutual empowerment between GBB’s AI‑driven site‑specific integration cell line development platform and the world‑class biopharma leader. AlfaCell efficiently addresses core industry pain points such as lengthy cell line development cycles, low productivity, unstable product quality and difficult pairing of complex molecules, accelerating the partner’s pipeline development and boosting efficiency. In return, the partner leverages its global manufacturing, regulatory and commercial networks to accelerate the international expansion of AlfaCell technologies for wider global biopharma R&D projects.
Jointly, both parties will shorten global new drug development timelines, cut R&D costs, bring more high‑quality biotherapeutics to patients worldwide, and inject strong momentum into the high‑quality development of the global biopharmaceutical industry.
